Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00364702 |
Recruitment Status :
Completed
First Posted : August 16, 2006
Last Update Posted : August 17, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
ADHD | Drug: methylphenidate | Phase 2 |
Virtual Reality is a novel program designed to imitate a real classroom environment including various distractions. It includes a head monitor to track eye movements Children aged 10-20 years with ADHD will use the program with and without methylphenidate(1 mg/kg). Their results will be compared to a control group.
Parental consent will be obtained.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Non-Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder |
Study Start Date : | August 2006 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | July 2007 |

- Virtual Reality program test results

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 10 Years to 20 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Clinical diagnosis of ADHD-DSM4 criteria AGE 10-20 YEARS normal neurological examination IQ>80
Exclusion Criteria:
ABNORMAL NEUROLOGICAL STATUS

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00364702
Israel | |
Shaari Zedek Pediatric Neurology Unit | |
Jerusalem, Israel, 91031 |
Study Chair: | V. Gross, Prof/ md | Shaari Zedek Pediatric Neurology Unit |
ClinicalTrials.gov Identifier: | NCT00364702 |
Other Study ID Numbers: |
45/04 |
First Posted: | August 16, 2006 Key Record Dates |
Last Update Posted: | August 17, 2011 |
Last Verified: | July 2006 |
Virtual Reality ADHD Methylphenidate |
Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Methylphenidate Central Nervous System Stimulants Physiological Effects of Drugs |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents |